NO329166B1 - Indolylmaleimidderivater, fremgangsmate for fremstilling derav, anvendelse av forbindelsene samt farmasoytisk sammensetning inneholdende en slik forbindelse. - Google Patents

Indolylmaleimidderivater, fremgangsmate for fremstilling derav, anvendelse av forbindelsene samt farmasoytisk sammensetning inneholdende en slik forbindelse. Download PDF

Info

Publication number: NO329166B1
Authority: NO; Norway
Prior art keywords: formula; compound; diseases; inflammatory; compounds
Prior art date: 2002-04-03

Application number

NO20044613A

Other languages

English (en)

Norwegian (no)

Other versions

NO20044613L (no

Inventor

Jean-Pierre Evenou

Peter Von Matt

J Rgen Wagner

Gerhard Zenke

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-04-03

Filing date

2004-10-26

Publication date

2010-09-06

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=28676503&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO329166(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2002-04-03 Priority claimed from GB0207729A external-priority patent/GB0207729D0/en

2003-02-13 Priority claimed from GB0303323A external-priority patent/GB0303323D0/en

2004-10-26 Application filed by Novartis Ag filed Critical Novartis Ag

2004-10-26 Publication of NO20044613L publication Critical patent/NO20044613L/no

2010-09-06 Publication of NO329166B1 publication Critical patent/NO329166B1/no

Links

150000001875 compounds Chemical class 0.000 title claims abstract description 72
239000008194 pharmaceutical composition Substances 0.000 title claims description 4
238000002360 preparation method Methods 0.000 title claims description 4
238000000034 method Methods 0.000 title description 11
WIQRSJOCVVPMPS-UHFFFAOYSA-N 3-(1h-indol-2-yl)pyrrole-2,5-dione Chemical class O=C1NC(=O)C(C=2NC3=CC=CC=C3C=2)=C1 WIQRSJOCVVPMPS-UHFFFAOYSA-N 0.000 title description 2
238000011282 treatment Methods 0.000 claims abstract description 9
230000001154 acute effect Effects 0.000 claims abstract description 8
230000001684 chronic effect Effects 0.000 claims abstract description 6
230000002265 prevention Effects 0.000 claims abstract description 5
208000009329 Graft vs Host Disease Diseases 0.000 claims abstract description 4
210000000056 organ Anatomy 0.000 claims abstract description 4
150000003839 salts Chemical class 0.000 claims description 19
238000006243 chemical reaction Methods 0.000 claims description 12
-1 4,7-diaza-spiro[2.5]oct-7-yl Chemical group 0.000 claims description 9
239000003085 diluting agent Substances 0.000 claims description 4
238000004519 manufacturing process Methods 0.000 claims description 4
125000003545 alkoxy group Chemical group 0.000 claims description 3
125000000217 alkyl group Chemical group 0.000 claims description 3
229910052736 halogen Inorganic materials 0.000 claims description 3
150000002367 halogens Chemical class 0.000 claims description 3
239000000825 pharmaceutical preparation Substances 0.000 claims description 3
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 2
239000008177 pharmaceutical agent Substances 0.000 claims description 2
125000001424 substituent group Chemical group 0.000 claims description 2
LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 2
KLSCBNKMNKJFBO-UHFFFAOYSA-N 3-[3-(4,7-diazaspiro[2.5]octan-7-yl)isoquinolin-1-yl]-4-(7-methyl-1h-indol-3-yl)pyrrole-2,5-dione Chemical group C=1NC=2C(C)=CC=CC=2C=1C(C(NC1=O)=O)=C1C(C1=CC=CC=C1C=1)=NC=1N(C1)CCNC21CC2 KLSCBNKMNKJFBO-UHFFFAOYSA-N 0.000 claims 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 12
230000002757 inflammatory effect Effects 0.000 abstract description 11
208000035475 disorder Diseases 0.000 abstract description 10
230000001404 mediated effect Effects 0.000 abstract description 7
210000001744 T-lymphocyte Anatomy 0.000 abstract description 6
206010012601 diabetes mellitus Diseases 0.000 abstract description 5
208000023275 Autoimmune disease Diseases 0.000 abstract description 4
206010001052 Acute respiratory distress syndrome Diseases 0.000 abstract description 3
206010012442 Dermatitis contact Diseases 0.000 abstract description 3
206010028980 Neoplasm Diseases 0.000 abstract description 3
201000000028 adult respiratory distress syndrome Diseases 0.000 abstract description 3
201000011510 cancer Diseases 0.000 abstract description 3
230000006378 damage Effects 0.000 abstract description 3
208000011580 syndromic disease Diseases 0.000 abstract description 3
208000030507 AIDS Diseases 0.000 abstract description 2
208000030090 Acute Disease Diseases 0.000 abstract description 2
208000024827 Alzheimer disease Diseases 0.000 abstract description 2
206010059245 Angiopathy Diseases 0.000 abstract description 2
201000001320 Atherosclerosis Diseases 0.000 abstract description 2
206010009900 Colitis ulcerative Diseases 0.000 abstract description 2
208000035473 Communicable disease Diseases 0.000 abstract description 2
208000011231 Crohn disease Diseases 0.000 abstract description 2
201000004624 Dermatitis Diseases 0.000 abstract description 2
206010012438 Dermatitis atopic Diseases 0.000 abstract description 2
208000007342 Diabetic Nephropathies Diseases 0.000 abstract description 2
208000032131 Diabetic Neuropathies Diseases 0.000 abstract description 2
206010012688 Diabetic retinal oedema Diseases 0.000 abstract description 2
208000002705 Glucose Intolerance Diseases 0.000 abstract description 2
208000030836 Hashimoto thyroiditis Diseases 0.000 abstract description 2
206010020772 Hypertension Diseases 0.000 abstract description 2
208000022559 Inflammatory bowel disease Diseases 0.000 abstract description 2
206010022680 Intestinal ischaemia Diseases 0.000 abstract description 2
206010067125 Liver injury Diseases 0.000 abstract description 2
208000008589 Obesity Diseases 0.000 abstract description 2
201000004681 Psoriasis Diseases 0.000 abstract description 2
208000001647 Renal Insufficiency Diseases 0.000 abstract description 2
206010063837 Reperfusion injury Diseases 0.000 abstract description 2
208000013616 Respiratory Distress Syndrome Diseases 0.000 abstract description 2
206010038934 Retinopathy proliferative Diseases 0.000 abstract description 2
206010039793 Seborrhoeic dermatitis Diseases 0.000 abstract description 2
206010040070 Septic Shock Diseases 0.000 abstract description 2
208000006011 Stroke Diseases 0.000 abstract description 2
206010044541 Traumatic shock Diseases 0.000 abstract description 2
201000006704 Ulcerative Colitis Diseases 0.000 abstract description 2
206010046851 Uveitis Diseases 0.000 abstract description 2
206010053648 Vascular occlusion Diseases 0.000 abstract description 2
208000011341 adult acute respiratory distress syndrome Diseases 0.000 abstract description 2
208000002029 allergic contact dermatitis Diseases 0.000 abstract description 2
206010002026 amyotrophic lateral sclerosis Diseases 0.000 abstract description 2
238000002399 angioplasty Methods 0.000 abstract description 2
208000006673 asthma Diseases 0.000 abstract description 2
201000008937 atopic dermatitis Diseases 0.000 abstract description 2
208000010668 atopic eczema Diseases 0.000 abstract description 2
230000000740 bleeding effect Effects 0.000 abstract description 2
208000015114 central nervous system disease Diseases 0.000 abstract description 2
208000037976 chronic inflammation Diseases 0.000 abstract description 2
208000037893 chronic inflammatory disorder Diseases 0.000 abstract description 2
208000033679 diabetic kidney disease Diseases 0.000 abstract description 2
201000010099 disease Diseases 0.000 abstract description 2
230000006806 disease prevention Effects 0.000 abstract description 2
208000030533 eye disease Diseases 0.000 abstract description 2
230000001434 glomerular Effects 0.000 abstract description 2
231100000234 hepatic damage Toxicity 0.000 abstract description 2
230000003463 hyperproliferative effect Effects 0.000 abstract description 2
208000028867 ischemia Diseases 0.000 abstract description 2
206010023332 keratitis Diseases 0.000 abstract description 2
201000010666 keratoconjunctivitis Diseases 0.000 abstract description 2
201000006370 kidney failure Diseases 0.000 abstract description 2
230000008818 liver damage Effects 0.000 abstract description 2
231100000516 lung damage Toxicity 0.000 abstract description 2
201000006417 multiple sclerosis Diseases 0.000 abstract description 2
208000010125 myocardial infarction Diseases 0.000 abstract description 2
230000007823 neuropathy Effects 0.000 abstract description 2
235000020824 obesity Nutrition 0.000 abstract description 2
201000008482 osteoarthritis Diseases 0.000 abstract description 2
201000010065 polycystic ovary syndrome Diseases 0.000 abstract description 2
201000009104 prediabetes syndrome Diseases 0.000 abstract description 2
208000023504 respiratory system disease Diseases 0.000 abstract description 2
208000037803 restenosis Diseases 0.000 abstract description 2
206010039073 rheumatoid arthritis Diseases 0.000 abstract description 2
208000008742 seborrheic dermatitis Diseases 0.000 abstract description 2
230000036303 septic shock Effects 0.000 abstract description 2
201000000596 systemic lupus erythematosus Diseases 0.000 abstract description 2
230000003966 vascular damage Effects 0.000 abstract description 2
208000021331 vascular occlusion disease Diseases 0.000 abstract description 2
240000007058 Halophila ovalis Species 0.000 abstract 1
208000019693 Lung disease Diseases 0.000 abstract 1
206010061876 Obstruction Diseases 0.000 abstract 1
206010038460 Renal haemorrhage Diseases 0.000 abstract 1
208000027418 Wounds and injury Diseases 0.000 abstract 1
230000000747 cardiac effect Effects 0.000 abstract 1
208000010247 contact dermatitis Diseases 0.000 abstract 1
201000011190 diabetic macular edema Diseases 0.000 abstract 1
208000024908 graft versus host disease Diseases 0.000 abstract 1
208000014674 injury Diseases 0.000 abstract 1
206010028417 myasthenia gravis Diseases 0.000 abstract 1
230000035939 shock Effects 0.000 abstract 1
230000000472 traumatic effect Effects 0.000 abstract 1
238000003556 assay Methods 0.000 description 22
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 18
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 18
102000003923 Protein Kinase C Human genes 0.000 description 16
108090000315 Protein Kinase C Proteins 0.000 description 16
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
210000004027 cell Anatomy 0.000 description 15
238000004458 analytical method Methods 0.000 description 11
239000000243 solution Substances 0.000 description 11
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 10
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
235000019439 ethyl acetate Nutrition 0.000 description 9
230000005764 inhibitory process Effects 0.000 description 8
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 8
239000007858 starting material Substances 0.000 description 8
238000012360 testing method Methods 0.000 description 8
108091003079 Bovine Serum Albumin Proteins 0.000 description 7
230000000694 effects Effects 0.000 description 7
XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 6
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 6
239000000203 mixture Substances 0.000 description 6
PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 description 6
239000002953 phosphate buffered saline Substances 0.000 description 6
241001465754 Metazoa Species 0.000 description 5
102000001253 Protein Kinase Human genes 0.000 description 5
238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 5
238000011534 incubation Methods 0.000 description 5
239000003112 inhibitor Substances 0.000 description 5
210000001165 lymph node Anatomy 0.000 description 5
108060006633 protein kinase Proteins 0.000 description 5
239000011541 reaction mixture Substances 0.000 description 5
102000005962 receptors Human genes 0.000 description 5
108020003175 receptors Proteins 0.000 description 5
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 4
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
108060001084 Luciferase Proteins 0.000 description 4
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
241000700159 Rattus Species 0.000 description 4
230000001028 anti-proliverative effect Effects 0.000 description 4
229940098773 bovine serum albumin Drugs 0.000 description 4
229940079593 drug Drugs 0.000 description 4
239000003814 drug Substances 0.000 description 4
230000002519 immonomodulatory effect Effects 0.000 description 4
230000001506 immunosuppresive effect Effects 0.000 description 4
229910052740 iodine Inorganic materials 0.000 description 4
PGHMRUGBZOYCAA-ADZNBVRBSA-N ionomycin Chemical compound O1[C@H](C[C@H](O)[C@H](C)[C@H](O)[C@H](C)/C=C/C[C@@H](C)C[C@@H](C)C(/O)=C/C(=O)[C@@H](C)C[C@@H](C)C[C@@H](CCC(O)=O)C)CC[C@@]1(C)[C@@H]1O[C@](C)([C@@H](C)O)CC1 PGHMRUGBZOYCAA-ADZNBVRBSA-N 0.000 description 4
PGHMRUGBZOYCAA-UHFFFAOYSA-N ionomycin Natural products O1C(CC(O)C(C)C(O)C(C)C=CCC(C)CC(C)C(O)=CC(=O)C(C)CC(C)CC(CCC(O)=O)C)CCC1(C)C1OC(C)(C(C)O)CC1 PGHMRUGBZOYCAA-UHFFFAOYSA-N 0.000 description 4
239000012044 organic layer Substances 0.000 description 4
238000011160 research Methods 0.000 description 4
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 4
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
239000005089 Luciferase Substances 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
239000003472 antidiabetic agent Substances 0.000 description 3
210000000709 aorta Anatomy 0.000 description 3
229910052786 argon Inorganic materials 0.000 description 3
239000003795 chemical substances by application Substances 0.000 description 3
239000012894 fetal calf serum Substances 0.000 description 3
238000000338 in vitro Methods 0.000 description 3
238000001727 in vivo Methods 0.000 description 3
230000002401 inhibitory effect Effects 0.000 description 3
238000005259 measurement Methods 0.000 description 3
229920006395 saturated elastomer Polymers 0.000 description 3
239000000725 suspension Substances 0.000 description 3
238000002560 therapeutic procedure Methods 0.000 description 3
210000001519 tissue Anatomy 0.000 description 3
NKOHRVBBQISBSB-UHFFFAOYSA-N 5-[(4-hydroxyphenyl)methyl]-1,3-thiazolidine-2,4-dione Chemical compound C1=CC(O)=CC=C1CC1C(=O)NC(=O)S1 NKOHRVBBQISBSB-UHFFFAOYSA-N 0.000 description 2
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 2
108010036949 Cyclosporine Proteins 0.000 description 2
108090000695 Cytokines Proteins 0.000 description 2
102000004127 Cytokines Human genes 0.000 description 2
102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 2
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 description 2
229940122199 Insulin secretagogue Drugs 0.000 description 2
102100025390 Integrin beta-2 Human genes 0.000 description 2
TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
SEQKRHFRPICQDD-UHFFFAOYSA-N N-tris(hydroxymethyl)methylglycine Chemical compound OCC(CO)(CO)[NH2+]CC([O-])=O SEQKRHFRPICQDD-UHFFFAOYSA-N 0.000 description 2
102000000536 PPAR gamma Human genes 0.000 description 2
108010016731 PPAR gamma Proteins 0.000 description 2
101150010978 PRKCE gene Proteins 0.000 description 2
229930182555 Penicillin Natural products 0.000 description 2
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
239000004743 Polypropylene Substances 0.000 description 2
108010029485 Protein Isoforms Proteins 0.000 description 2
102000001708 Protein Isoforms Human genes 0.000 description 2
108700008625 Reporter Genes Proteins 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
230000006044 T cell activation Effects 0.000 description 2
230000006052 T cell proliferation Effects 0.000 description 2
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
230000003187 abdominal effect Effects 0.000 description 2
239000013543 active substance Substances 0.000 description 2
239000000556 agonist Substances 0.000 description 2
229910000147 aluminium phosphate Inorganic materials 0.000 description 2
VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 2
239000005557 antagonist Substances 0.000 description 2
230000003178 anti-diabetic effect Effects 0.000 description 2
230000003110 anti-inflammatory effect Effects 0.000 description 2
239000012298 atmosphere Substances 0.000 description 2
238000010009 beating Methods 0.000 description 2
MUALRAIOVNYAIW-UHFFFAOYSA-N binap Chemical group C1=CC=CC=C1P(C=1C(=C2C=CC=CC2=CC=1)C=1C2=CC=CC=C2C=CC=1P(C=1C=CC=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 MUALRAIOVNYAIW-UHFFFAOYSA-N 0.000 description 2
230000029918 bioluminescence Effects 0.000 description 2
238000005415 bioluminescence Methods 0.000 description 2
229910052794 bromium Inorganic materials 0.000 description 2
229910052799 carbon Inorganic materials 0.000 description 2
125000004432 carbon atom Chemical group C* 0.000 description 2
229910052801 chlorine Inorganic materials 0.000 description 2
229960001265 ciclosporin Drugs 0.000 description 2
238000001816 cooling Methods 0.000 description 2
229930182912 cyclosporin Natural products 0.000 description 2
239000003937 drug carrier Substances 0.000 description 2
229910052731 fluorine Inorganic materials 0.000 description 2
102000054766 genetic haplotypes Human genes 0.000 description 2
229960004580 glibenclamide Drugs 0.000 description 2
ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 2
FFUAGWLWBBFQJT-UHFFFAOYSA-N hexamethyldisilazane Chemical compound C[Si](C)(C)N[Si](C)(C)C FFUAGWLWBBFQJT-UHFFFAOYSA-N 0.000 description 2
208000027866 inflammatory disease Diseases 0.000 description 2
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
229940124302 mTOR inhibitor Drugs 0.000 description 2
239000003628 mammalian target of rapamycin inhibitor Substances 0.000 description 2
238000002156 mixing Methods 0.000 description 2
KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
229940049954 penicillin Drugs 0.000 description 2
229920001155 polypropylene Polymers 0.000 description 2
LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 2
230000035755 proliferation Effects 0.000 description 2
238000000159 protein binding assay Methods 0.000 description 2
210000001147 pulmonary artery Anatomy 0.000 description 2
238000000746 purification Methods 0.000 description 2
238000010992 reflux Methods 0.000 description 2
238000013207 serial dilution Methods 0.000 description 2
229960002930 sirolimus Drugs 0.000 description 2
239000002904 solvent Substances 0.000 description 2
210000004989 spleen cell Anatomy 0.000 description 2
238000010561 standard procedure Methods 0.000 description 2
229960005322 streptomycin Drugs 0.000 description 2
239000000758 substrate Substances 0.000 description 2
230000004083 survival effect Effects 0.000 description 2
229940104230 thymidine Drugs 0.000 description 2
238000011200 topical administration Methods 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
BLWKWOVOFWHFLD-FQEVSTJZSA-N (2s)-2-(2-benzoylanilino)-3-(4-hydroxyphenyl)propanoic acid Chemical class C([C@@H](C(=O)O)NC=1C(=CC=CC=1)C(=O)C=1C=CC=CC=1)C1=CC=C(O)C=C1 BLWKWOVOFWHFLD-FQEVSTJZSA-N 0.000 description 1
BRGZEQXWZWBPJH-UHFFFAOYSA-N 1,3-dichloroisoquinoline Chemical compound C1=CC=C2C(Cl)=NC(Cl)=CC2=C1 BRGZEQXWZWBPJH-UHFFFAOYSA-N 0.000 description 1
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
BOVGTQGAOIONJV-BETUJISGSA-N 1-[(3ar,6as)-3,3a,4,5,6,6a-hexahydro-1h-cyclopenta[c]pyrrol-2-yl]-3-(4-methylphenyl)sulfonylurea Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NN1C[C@H]2CCC[C@H]2C1 BOVGTQGAOIONJV-BETUJISGSA-N 0.000 description 1
LLJFMFZYVVLQKT-UHFFFAOYSA-N 1-cyclohexyl-3-[4-[2-(7-methoxy-4,4-dimethyl-1,3-dioxo-2-isoquinolinyl)ethyl]phenyl]sulfonylurea Chemical compound C=1C(OC)=CC=C(C(C2=O)(C)C)C=1C(=O)N2CCC(C=C1)=CC=C1S(=O)(=O)NC(=O)NC1CCCCC1 LLJFMFZYVVLQKT-UHFFFAOYSA-N 0.000 description 1
NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
ZEMZPXWZVTUONV-UHFFFAOYSA-N 2-(2-dicyclohexylphosphanylphenyl)-n,n-dimethylaniline Chemical compound CN(C)C1=CC=CC=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 ZEMZPXWZVTUONV-UHFFFAOYSA-N 0.000 description 1
UMAWPTUPNQKLHV-UHFFFAOYSA-N 2-[3-(4,7-diazaspiro[2.5]octan-7-yl)isoquinolin-1-yl]acetamide Chemical compound C=1C2=CC=CC=C2C(CC(=O)N)=NC=1N(C1)CCNC21CC2 UMAWPTUPNQKLHV-UHFFFAOYSA-N 0.000 description 1
DCUMZKOSBMHRLT-UHFFFAOYSA-N 2-[3-(4-benzyl-4,7-diazaspiro[2.5]octan-7-yl)isoquinolin-1-yl]acetamide;ethyl 2-[3-(4-benzyl-4,7-diazaspiro[2.5]octan-7-yl)isoquinolin-1-yl]acetate Chemical compound C=1C2=CC=CC=C2C(CC(=O)N)=NC=1N(CC12CC2)CCN1CC1=CC=CC=C1.C=1C2=CC=CC=C2C(CC(=O)OCC)=NC=1N(CC12CC2)CCN1CC1=CC=CC=C1 DCUMZKOSBMHRLT-UHFFFAOYSA-N 0.000 description 1
WHNQTHDJEZTVHS-UHFFFAOYSA-N 3-(1,3-benzothiazol-2-yl)propanoic acid Chemical compound C1=CC=C2SC(CCC(=O)O)=NC2=C1 WHNQTHDJEZTVHS-UHFFFAOYSA-N 0.000 description 1
SWLAMJPTOQZTAE-UHFFFAOYSA-N 4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]benzoic acid Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(C(O)=O)C=C1 SWLAMJPTOQZTAE-UHFFFAOYSA-N 0.000 description 1
QBQLYIISSRXYKL-UHFFFAOYSA-N 4-[[4-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]phenyl]methyl]-1,2-oxazolidine-3,5-dione Chemical compound CC=1OC(C=2C=CC=CC=2)=NC=1CCOC(C=C1)=CC=C1CC1C(=O)NOC1=O QBQLYIISSRXYKL-UHFFFAOYSA-N 0.000 description 1
CSELKLIMQOUJMY-UHFFFAOYSA-N 4-benzyl-4,7-diazaspiro[2.5]octane Chemical compound C=1C=CC=CC=1CN1CCNCC11CC1 CSELKLIMQOUJMY-UHFFFAOYSA-N 0.000 description 1
SHGAZHPCJJPHSC-ZVCIMWCZSA-N 9-cis-retinoic acid Chemical compound OC(=O)/C=C(\C)/C=C/C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-ZVCIMWCZSA-N 0.000 description 1
238000011725 BALB/c mouse Methods 0.000 description 1
239000005711 Benzoic acid Substances 0.000 description 1
229940122361 Bisphosphonate Drugs 0.000 description 1
241000208199 Buxus sempervirens Species 0.000 description 1
238000011749 CBA mouse Methods 0.000 description 1
101150013553 CD40 gene Proteins 0.000 description 1
108010021064 CTLA-4 Antigen Proteins 0.000 description 1
102000008203 CTLA-4 Antigen Human genes 0.000 description 1
241000283707 Capra Species 0.000 description 1
RKWGIWYCVPQPMF-UHFFFAOYSA-N Chloropropamide Chemical compound CCCNC(=O)NS(=O)(=O)C1=CC=C(Cl)C=C1 RKWGIWYCVPQPMF-UHFFFAOYSA-N 0.000 description 1
208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
RGJOEKWQDUBAIZ-IBOSZNHHSA-N CoASH Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCS)O[C@H]1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-IBOSZNHHSA-N 0.000 description 1
102000005636 Cyclic AMP Response Element-Binding Protein Human genes 0.000 description 1
108010045171 Cyclic AMP Response Element-Binding Protein Proteins 0.000 description 1
CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
229930105110 Cyclosporin A Natural products 0.000 description 1
108010036941 Cyclosporins Proteins 0.000 description 1
IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
229940123780 DNA topoisomerase I inhibitor Drugs 0.000 description 1
229940124087 DNA topoisomerase II inhibitor Drugs 0.000 description 1
CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
102100025012 Dipeptidyl peptidase 4 Human genes 0.000 description 1
102000036530 EDG receptors Human genes 0.000 description 1
108091007263 EDG receptors Proteins 0.000 description 1
BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
102100025101 GATA-type zinc finger protein 1 Human genes 0.000 description 1
101710198884 GATA-type zinc finger protein 1 Chemical class 0.000 description 1
DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical class C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 1
FAEKWTJYAYMJKF-QHCPKHFHSA-N GlucoNorm Chemical compound C1=C(C(O)=O)C(OCC)=CC(CC(=O)N[C@@H](CC(C)C)C=2C(=CC=CC=2)N2CCCCC2)=C1 FAEKWTJYAYMJKF-QHCPKHFHSA-N 0.000 description 1
HNSCCNJWTJUGNQ-UHFFFAOYSA-N Glyclopyramide Chemical compound C1=CC(Cl)=CC=C1S(=O)(=O)NC(=O)NN1CCCC1 HNSCCNJWTJUGNQ-UHFFFAOYSA-N 0.000 description 1
102000019058 Glycogen Synthase Kinase 3 beta Human genes 0.000 description 1
108010051975 Glycogen Synthase Kinase 3 beta Proteins 0.000 description 1
102400000932 Gonadoliberin-1 Human genes 0.000 description 1
206010019280 Heart failures Diseases 0.000 description 1
208000032843 Hemorrhage Diseases 0.000 description 1
208000032456 Hemorrhagic Shock Diseases 0.000 description 1
241000282412 Homo Species 0.000 description 1
101500026183 Homo sapiens Gonadoliberin-1 Proteins 0.000 description 1
101000935040 Homo sapiens Integrin beta-2 Proteins 0.000 description 1
101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 1
101001002657 Homo sapiens Interleukin-2 Proteins 0.000 description 1
101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 1
101001063392 Homo sapiens Lymphocyte function-associated antigen 3 Proteins 0.000 description 1
101000684208 Homo sapiens Prolyl endopeptidase FAP Proteins 0.000 description 1
101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 1
101000914496 Homo sapiens T-cell antigen CD7 Proteins 0.000 description 1
101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 1
102000004877 Insulin Human genes 0.000 description 1
108090001061 Insulin Proteins 0.000 description 1
108010008212 Integrin alpha4beta1 Proteins 0.000 description 1
102000000588 Interleukin-2 Human genes 0.000 description 1
108010002350 Interleukin-2 Proteins 0.000 description 1
102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 1
108010044467 Isoenzymes Proteins 0.000 description 1
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 description 1
102100030984 Lymphocyte function-associated antigen 3 Human genes 0.000 description 1
229940124761 MMP inhibitor Drugs 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
102000029749 Microtubule Human genes 0.000 description 1
108091022875 Microtubule Proteins 0.000 description 1
HZQDCMWJEBCWBR-UUOKFMHZSA-N Mizoribine Chemical compound OC1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 HZQDCMWJEBCWBR-UUOKFMHZSA-N 0.000 description 1
HIEKJRVYXXINKH-ADVKXBNGSA-N N1([C@H]2CC[C@H](C[C@H]2OC)/C=C(\C)[C@H]2OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@]3(O)O[C@@H]([C@H](C[C@H]3C)OC)[C@@H](OC)C[C@@H](C)C/C(C)=C/[C@H](C(C[C@H](O)[C@H]2C)=O)CC)C=NN=N1 Chemical compound N1([C@H]2CC[C@H](C[C@H]2OC)/C=C(\C)[C@H]2OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@]3(O)O[C@@H]([C@H](C[C@H]3C)OC)[C@@H](OC)C[C@@H](C)C/C(C)=C/[C@H](C(C[C@H](O)[C@H]2C)=O)CC)C=NN=N1 HIEKJRVYXXINKH-ADVKXBNGSA-N 0.000 description 1
102000023984 PPAR alpha Human genes 0.000 description 1
101150020891 PRKCA gene Proteins 0.000 description 1
229940080774 Peroxisome proliferator-activated receptor gamma agonist Drugs 0.000 description 1
OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
108010007568 Protamines Proteins 0.000 description 1
102000007327 Protamines Human genes 0.000 description 1
239000012979 RPMI medium Substances 0.000 description 1
239000012980 RPMI-1640 medium Substances 0.000 description 1
102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 1
229940121908 Retinoid X receptor agonist Drugs 0.000 description 1
206010049771 Shock haemorrhagic Diseases 0.000 description 1
208000021386 Sjogren Syndrome Diseases 0.000 description 1
229940100389 Sulfonylurea Drugs 0.000 description 1
UZMAPBJVXOGOFT-UHFFFAOYSA-N Syringetin Natural products COC1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UZMAPBJVXOGOFT-UHFFFAOYSA-N 0.000 description 1
102100027208 T-cell antigen CD7 Human genes 0.000 description 1
102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 1
QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 1
BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 1
CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 description 1
JLRGJRBPOGGCBT-UHFFFAOYSA-N Tolbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 JLRGJRBPOGGCBT-UHFFFAOYSA-N 0.000 description 1
239000000365 Topoisomerase I Inhibitor Substances 0.000 description 1
239000000317 Topoisomerase II Inhibitor Substances 0.000 description 1
206010052779 Transplant rejections Diseases 0.000 description 1
208000030886 Traumatic Brain injury Diseases 0.000 description 1
239000007997 Tricine buffer Substances 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
229920004890 Triton X-100 Polymers 0.000 description 1
239000013504 Triton X-100 Substances 0.000 description 1
102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 1
210000003815 abdominal wall Anatomy 0.000 description 1
159000000021 acetate salts Chemical class 0.000 description 1
229960001466 acetohexamide Drugs 0.000 description 1
VGZSUPCWNCWDAN-UHFFFAOYSA-N acetohexamide Chemical compound C1=CC(C(=O)C)=CC=C1S(=O)(=O)NC(=O)NC1CCCCC1 VGZSUPCWNCWDAN-UHFFFAOYSA-N 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
238000013019 agitation Methods 0.000 description 1
229960001445 alitretinoin Drugs 0.000 description 1
229940100198 alkylating agent Drugs 0.000 description 1
239000002168 alkylating agent Substances 0.000 description 1
230000000735 allogeneic effect Effects 0.000 description 1
230000003872 anastomosis Effects 0.000 description 1
230000002280 anti-androgenic effect Effects 0.000 description 1
230000001772 anti-angiogenic effect Effects 0.000 description 1
229940127003 anti-diabetic drug Drugs 0.000 description 1
229940046836 anti-estrogen Drugs 0.000 description 1
230000001833 anti-estrogenic effect Effects 0.000 description 1
239000002260 anti-inflammatory agent Substances 0.000 description 1
229940121363 anti-inflammatory agent Drugs 0.000 description 1
239000000051 antiandrogen Substances 0.000 description 1
229940030495 antiandrogen sex hormone and modulator of the genital system Drugs 0.000 description 1
239000002246 antineoplastic agent Substances 0.000 description 1
239000002814 antineoplastic antimetabolite Substances 0.000 description 1
229940045985 antineoplastic platinum compound Drugs 0.000 description 1
210000000702 aorta abdominal Anatomy 0.000 description 1
239000003886 aromatase inhibitor Substances 0.000 description 1
229940046844 aromatase inhibitors Drugs 0.000 description 1
239000012911 assay medium Substances 0.000 description 1
229930195545 bengamide Natural products 0.000 description 1
150000004663 bisphosphonates Chemical class 0.000 description 1
230000037396 body weight Effects 0.000 description 1
239000002775 capsule Substances 0.000 description 1
229910002091 carbon monoxide Inorganic materials 0.000 description 1
229960003362 carbutamide Drugs 0.000 description 1
VDTNNGKXZGSZIP-UHFFFAOYSA-N carbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(N)C=C1 VDTNNGKXZGSZIP-UHFFFAOYSA-N 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
229940044683 chemotherapy drug Drugs 0.000 description 1
229960001761 chlorpropamide Drugs 0.000 description 1
RGJOEKWQDUBAIZ-UHFFFAOYSA-N coenzime A Natural products OC1C(OP(O)(O)=O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-UHFFFAOYSA-N 0.000 description 1
239000005516 coenzyme A Substances 0.000 description 1
229940093530 coenzyme a Drugs 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
239000003246 corticosteroid Substances 0.000 description 1
229960001334 corticosteroids Drugs 0.000 description 1
230000004940 costimulation Effects 0.000 description 1
229940111134 coxibs Drugs 0.000 description 1
239000006071 cream Substances 0.000 description 1
239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 1
229960004397 cyclophosphamide Drugs 0.000 description 1
KDTSHFARGAKYJN-UHFFFAOYSA-N dephosphocoenzyme A Natural products OC1C(O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 KDTSHFARGAKYJN-UHFFFAOYSA-N 0.000 description 1
WMKGGPCROCCUDY-PHEQNACWSA-N dibenzylideneacetone Chemical compound C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 WMKGGPCROCCUDY-PHEQNACWSA-N 0.000 description 1
KCFYHBSOLOXZIF-UHFFFAOYSA-N dihydrochrysin Natural products COC1=C(O)C(OC)=CC(C2OC3=CC(O)=CC(O)=C3C(=O)C2)=C1 KCFYHBSOLOXZIF-UHFFFAOYSA-N 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
238000002224 dissection Methods 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
230000009977 dual effect Effects 0.000 description 1
239000000328 estrogen antagonist Substances 0.000 description 1
WYLOJIDTEWMKKS-UHFFFAOYSA-N ethyl 2-(3-chloroisoquinolin-1-yl)acetate Chemical compound C1=CC=C2C(CC(=O)OCC)=NC(Cl)=CC2=C1 WYLOJIDTEWMKKS-UHFFFAOYSA-N 0.000 description 1
HGPNCSYBHVVIIK-UHFFFAOYSA-N ethyl 2-[3-(4-benzyl-4,7-diazaspiro[2.5]octan-7-yl)isoquinolin-1-yl]acetate;ethyl 2-(3-chloroisoquinolin-1-yl)acetate Chemical compound C1=CC=C2C(CC(=O)OCC)=NC(Cl)=CC2=C1.C=1C2=CC=CC=C2C(CC(=O)OCC)=NC=1N(CC12CC2)CCN1CC1=CC=CC=C1 HGPNCSYBHVVIIK-UHFFFAOYSA-N 0.000 description 1
125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 description 1
238000000605 extraction Methods 0.000 description 1
238000001914 filtration Methods 0.000 description 1
229960000556 fingolimod Drugs 0.000 description 1
KKGQTZUTZRNORY-UHFFFAOYSA-N fingolimod Chemical compound CCCCCCCCC1=CC=C(CCC(N)(CO)CO)C=C1 KKGQTZUTZRNORY-UHFFFAOYSA-N 0.000 description 1
238000003818 flash chromatography Methods 0.000 description 1
210000002683 foot Anatomy 0.000 description 1
239000000499 gel Substances 0.000 description 1
229960000346 gliclazide Drugs 0.000 description 1
229960001381 glipizide Drugs 0.000 description 1
ZJJXGWJIGJFDTL-UHFFFAOYSA-N glipizide Chemical compound C1=NC(C)=CN=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZJJXGWJIGJFDTL-UHFFFAOYSA-N 0.000 description 1
229960003468 gliquidone Drugs 0.000 description 1
229960003236 glisoxepide Drugs 0.000 description 1
ZKUDBRCEOBOWLF-UHFFFAOYSA-N glisoxepide Chemical compound O1C(C)=CC(C(=O)NCCC=2C=CC(=CC=2)S(=O)(=O)NC(=O)NN2CCCCCC2)=N1 ZKUDBRCEOBOWLF-UHFFFAOYSA-N 0.000 description 1
239000003877 glucagon like peptide 1 receptor agonist Chemical class 0.000 description 1
NFRPNQDSKJJQGV-UHFFFAOYSA-N glyhexamide Chemical compound C=1C=C2CCCC2=CC=1S(=O)(=O)NC(=O)NC1CCCCC1 NFRPNQDSKJJQGV-UHFFFAOYSA-N 0.000 description 1
229950008290 glyhexamide Drugs 0.000 description 1
QFWPJPIVLCBXFJ-UHFFFAOYSA-N glymidine Chemical compound N1=CC(OCCOC)=CN=C1NS(=O)(=O)C1=CC=CC=C1 QFWPJPIVLCBXFJ-UHFFFAOYSA-N 0.000 description 1
229960004440 glymidine Drugs 0.000 description 1
RHQSNARBXHRBNP-UHFFFAOYSA-N glypinamide Chemical compound C1=CC(Cl)=CC=C1S(=O)(=O)NC(=O)NN1CCCCCC1 RHQSNARBXHRBNP-UHFFFAOYSA-N 0.000 description 1
229950009188 glypinamide Drugs 0.000 description 1
XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 description 1
229960001442 gonadorelin Drugs 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
210000000548 hind-foot Anatomy 0.000 description 1
229940121372 histone deacetylase inhibitor Drugs 0.000 description 1
239000003276 histone deacetylase inhibitor Substances 0.000 description 1
102000055277 human IL2 Human genes 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
229940125396 insulin Drugs 0.000 description 1
230000002473 insulinotropic effect Effects 0.000 description 1
239000002555 ionophore Substances 0.000 description 1
230000000236 ionophoric effect Effects 0.000 description 1
208000001875 irritant dermatitis Diseases 0.000 description 1
229960000681 leflunomide Drugs 0.000 description 1
VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 description 1
210000000265 leukocyte Anatomy 0.000 description 1
239000003446 ligand Substances 0.000 description 1
DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 1
239000006210 lotion Substances 0.000 description 1
210000004698 lymphocyte Anatomy 0.000 description 1
230000000527 lymphocytic effect Effects 0.000 description 1
239000012139 lysis buffer Substances 0.000 description 1
239000001095 magnesium carbonate Substances 0.000 description 1
ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
235000014380 magnesium carbonate Nutrition 0.000 description 1
229910000021 magnesium carbonate Inorganic materials 0.000 description 1
229910001629 magnesium chloride Inorganic materials 0.000 description 1
YIXJRHPUWRPCBB-UHFFFAOYSA-N magnesium nitrate Inorganic materials [Mg+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O YIXJRHPUWRPCBB-UHFFFAOYSA-N 0.000 description 1
229910052943 magnesium sulfate Inorganic materials 0.000 description 1
235000019341 magnesium sulphate Nutrition 0.000 description 1
229950004994 meglitinide Drugs 0.000 description 1
239000012528 membrane Substances 0.000 description 1
229960000485 methotrexate Drugs 0.000 description 1
MHKYKAZMQYFAMW-UHFFFAOYSA-N methyl 2-(7-methyl-1h-indol-3-yl)-2-oxoacetate Chemical compound C1=CC=C2C(C(=O)C(=O)OC)=CNC2=C1C MHKYKAZMQYFAMW-UHFFFAOYSA-N 0.000 description 1
HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 1
210000004688 microtubule Anatomy 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
229950000844 mizoribine Drugs 0.000 description 1
RTGDFNSFWBGLEC-SYZQJQIISA-N mycophenolate mofetil Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-SYZQJQIISA-N 0.000 description 1
229960004866 mycophenolate mofetil Drugs 0.000 description 1
229960000951 mycophenolic acid Drugs 0.000 description 1
HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 1
MZRVEZGGRBJDDB-UHFFFAOYSA-N n-Butyllithium Substances [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 1
OELFLUMRDSZNSF-BRWVUGGUSA-N nateglinide Chemical compound C1C[C@@H](C(C)C)CC[C@@H]1C(=O)N[C@@H](C(O)=O)CC1=CC=CC=C1 OELFLUMRDSZNSF-BRWVUGGUSA-N 0.000 description 1
229960000698 nateglinide Drugs 0.000 description 1
239000002674 ointment Substances 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
LXNAVEXFUKBNMK-UHFFFAOYSA-N palladium(II) acetate Substances [Pd].CC(O)=O.CC(O)=O LXNAVEXFUKBNMK-UHFFFAOYSA-N 0.000 description 1
YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 1
238000002559 palpation Methods 0.000 description 1
108091008725 peroxisome proliferator-activated receptors alpha Proteins 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
AFOGBLYPWJJVAL-UHFFFAOYSA-N phenbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=CC=C1 AFOGBLYPWJJVAL-UHFFFAOYSA-N 0.000 description 1
229950008557 phenbutamide Drugs 0.000 description 1
WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical class OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
229940080469 phosphocellulose Drugs 0.000 description 1
KASDHRXLYQOAKZ-XDSKOBMDSA-N pimecrolimus Chemical compound C/C([C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@@H](OC)C[C@@H](C)C/C(C)=C/[C@H](C(C[C@H](O)[C@H]1C)=O)CC)=C\[C@@H]1CC[C@H](Cl)[C@H](OC)C1 KASDHRXLYQOAKZ-XDSKOBMDSA-N 0.000 description 1
125000004193 piperazinyl group Chemical group 0.000 description 1
150000003058 platinum compounds Chemical class 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
230000009696 proliferative response Effects 0.000 description 1
229950008679 protamine sulfate Drugs 0.000 description 1
239000003528 protein farnesyltransferase inhibitor Substances 0.000 description 1
ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
239000011535 reaction buffer Substances 0.000 description 1
229940044601 receptor agonist Drugs 0.000 description 1
239000000018 receptor agonist Substances 0.000 description 1
229960002354 repaglinide Drugs 0.000 description 1
239000002412 selectin antagonist Substances 0.000 description 1
230000001235 sensitizing effect Effects 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
208000017520 skin disease Diseases 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 1
239000007790 solid phase Substances 0.000 description 1
125000002345 steroid group Chemical group 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
238000003756 stirring Methods 0.000 description 1
YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
239000000829 suppository Substances 0.000 description 1
229960004964 temozolomide Drugs 0.000 description 1
229960000235 temsirolimus Drugs 0.000 description 1
PVLJDNHSECLKTF-UHFFFAOYSA-N tert-butyl 2-(3-chloroisoquinolin-1-yl)acetate Chemical compound C1=CC=C2C(CC(=O)OC(C)(C)C)=NC(Cl)=CC2=C1 PVLJDNHSECLKTF-UHFFFAOYSA-N 0.000 description 1
FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 1
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
OUDSBRTVNLOZBN-UHFFFAOYSA-N tolazamide Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NN1CCCCCC1 OUDSBRTVNLOZBN-UHFFFAOYSA-N 0.000 description 1
229960002277 tolazamide Drugs 0.000 description 1
229960005371 tolbutamide Drugs 0.000 description 1
238000002054 transplantation Methods 0.000 description 1
230000009529 traumatic brain injury Effects 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
JLEXUIVKURIPFI-UHFFFAOYSA-N tris phosphate Chemical compound OP(O)(O)=O.OCC(N)(CO)CO JLEXUIVKURIPFI-UHFFFAOYSA-N 0.000 description 1
210000001631 vena cava inferior Anatomy 0.000 description 1
SYOKIDBDQMKNDQ-XWTIBIIYSA-N vildagliptin Chemical class C1C(O)(C2)CC(C3)CC1CC32NCC(=O)N1CCC[C@H]1C#N SYOKIDBDQMKNDQ-XWTIBIIYSA-N 0.000 description 1
238000005406 washing Methods 0.000 description 1
229950009819 zotarolimus Drugs 0.000 description 1
CGTADGCBEXYWNE-JUKNQOCSSA-N zotarolimus Chemical compound N1([C@H]2CC[C@@H](C[C@@H](C)[C@H]3OC(=O)[C@@H]4CCCCN4C(=O)C(=O)[C@@]4(O)[C@H](C)CC[C@H](O4)C[C@@H](/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C3)OC)C[C@H]2OC)C=NN=N1 CGTADGCBEXYWNE-JUKNQOCSSA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Cardiology (AREA)
Diabetes (AREA)
Dermatology (AREA)
Heart & Thoracic Surgery (AREA)
Neurology (AREA)
Pulmonology (AREA)
Hematology (AREA)
Neurosurgery (AREA)
Communicable Diseases (AREA)
Biomedical Technology (AREA)
Oncology (AREA)
Urology & Nephrology (AREA)
Physical Education & Sports Medicine (AREA)
Epidemiology (AREA)
Rheumatology (AREA)
Hospice & Palliative Care (AREA)
Orthopedic Medicine & Surgery (AREA)
Obesity (AREA)
Virology (AREA)
Vascular Medicine (AREA)
Child & Adolescent Psychology (AREA)
Tropical Medicine & Parasitology (AREA)
Molecular Biology (AREA)
Psychiatry (AREA)

NO20044613A 2002-04-03 2004-10-26 Indolylmaleimidderivater, fremgangsmate for fremstilling derav, anvendelse av forbindelsene samt farmasoytisk sammensetning inneholdende en slik forbindelse. NO329166B1 (no)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GB0207729A GB0207729D0 (en)	2002-04-03	2002-04-03	Organic compounds
GB0303323A GB0303323D0 (en)	2003-02-13	2003-02-13	Organic compounds
PCT/EP2003/003470 WO2003082859A1 (en)	2002-04-03	2003-04-02	Indolylmaleimide derivatives

Publications (2)

Publication Number	Publication Date
NO20044613L NO20044613L (no)	2004-10-26
NO329166B1 true NO329166B1 (no)	2010-09-06

Family

ID=28676503

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20044613A NO329166B1 (no)	2002-04-03	2004-10-26	Indolylmaleimidderivater, fremgangsmate for fremstilling derav, anvendelse av forbindelsene samt farmasoytisk sammensetning inneholdende en slik forbindelse.

Country Status (26)

Country	Link
US (5)	US20050119274A1 (pl)
EP (1)	EP1490355B1 (pl)
JP (1)	JP4247125B2 (pl)
KR (2)	KR100942329B1 (pl)
CN (1)	CN100351251C (pl)
AR (1)	AR039209A1 (pl)
AT (1)	ATE517888T1 (pl)
AU (1)	AU2003224031B2 (pl)
BR (1)	BR0308979A (pl)
CA (1)	CA2477774C (pl)
CO (1)	CO5611127A2 (pl)
CY (1)	CY1111982T1 (pl)
DK (1)	DK1490355T3 (pl)
EC (2)	ECSP045254A (pl)
IL (1)	IL163892A0 (pl)
MX (1)	MXPA04009632A (pl)
MY (1)	MY137566A (pl)
NO (1)	NO329166B1 (pl)
NZ (1)	NZ535613A (pl)
PE (1)	PE20040079A1 (pl)
PL (1)	PL213480B1 (pl)
PT (1)	PT1490355E (pl)
RU (1)	RU2340610C2 (pl)
SI (1)	SI1490355T1 (pl)
TW (2)	TWI324064B (pl)
WO (1)	WO2003082859A1 (pl)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6645970B2 (en) *	2000-11-07	2003-11-11	Novartis Ag	Indolylmaleimide derivatives
PE20040079A1 (es) *	2002-04-03	2004-04-19	Novartis Ag	Derivados de indolilmaleimida
GB0303319D0 (en) *	2003-02-13	2003-03-19	Novartis Ag	Organic compounds
US7550590B2 (en)	2003-03-25	2009-06-23	Takeda Pharmaceutical Company Limited	Dipeptidyl peptidase inhibitors
WO2004103993A1 (en)	2003-05-14	2004-12-02	Syrrx, Inc.	Dipeptidyl peptidase inhibitors
KR20060041309A (ko)	2003-08-13	2006-05-11	다케다 야쿠힌 고교 가부시키가이샤	４-피리미돈 유도체 및 펩티딜 펩티다제 저해제로서의 그의용도
US20070142401A1 (en) *	2003-10-27	2007-06-21	Novartis Ag	Indolyl-pyrroledione derivatives for the treatment of neurological and vascular disorders related to beta-amyloid generation and/or aggregation
US7582631B2 (en) *	2004-01-14	2009-09-01	Amgen Inc.	Substituted heterocyclic compounds and methods of use
BRPI0506939A (pt) *	2004-01-19	2007-06-12	Novartis Ag	derivados de indolilmaleimida como inibidores de pkc
JP2007532506A (ja) *	2004-04-08	2007-11-15	ノバルティスアクチエンゲゼルシャフト	自己免疫疾患および拒絶反応の処置のためのタンパク質キナーゼｃ阻害剤
GB0410713D0 (en)	2004-05-13	2004-06-16	Novartis Ag	Organic compounds
GB0504203D0 (en) *	2005-03-01	2005-04-06	Novartis Ag	Organic compounds
JP4747364B2 (ja)	2005-04-04	2011-08-17	独立行政法人産業技術総合研究所	紫外線皮膚炎抑止剤およびアトピー性皮膚炎抑止剤
GB0507918D0 (en)	2005-04-19	2005-05-25	Novartis Ag	Organic compounds
US20080207594A1 (en)	2005-05-04	2008-08-28	Davelogen Aktiengesellschaft	Use of Gsk-3 Inhibitors for Preventing and Treating Pancreatic Autoimmune Disorders
GB0511060D0 (en)	2005-05-31	2005-07-06	Novartis Ag	Organic compounds
AU2006268908A1 (en) *	2005-07-11	2007-01-18	Novartis Ag	Indolylmaleimide derivatives
EP1749523A1 (en) *	2005-07-29	2007-02-07	Neuropharma, S.A.	GSK-3 inhibitors
EP2258358A3 (en)	2005-08-26	2011-09-07	Braincells, Inc.	Neurogenesis with acetylcholinesterase inhibitor
EP1928437A2 (en)	2005-08-26	2008-06-11	Braincells, Inc.	Neurogenesis by muscarinic receptor modulation
GEP20135838B (en)	2005-09-14	2013-06-10	Takeda Pharmaceutical	Dipeptidyl peptidase inhibitors usage at diabetes treatment
CN101360723A (zh)	2005-09-16	2009-02-04	武田药品工业株式会社	制备嘧啶二酮衍生物的方法
EP1940389A2 (en)	2005-10-21	2008-07-09	Braincells, Inc.	Modulation of neurogenesis by pde inhibition
TR201802449T4 (tr)	2005-10-26	2018-03-21	Novartis Ag	Ailesel akdeniz hummasının anti ıl-1beta antikorları ile tedavisi.
US20070112017A1 (en)	2005-10-31	2007-05-17	Braincells, Inc.	Gaba receptor mediated modulation of neurogenesis
RU2487711C2 (ru)	2005-11-21	2013-07-20	Новартис Аг	Лечение нейроэндокринных опухолей
GB0601744D0 (en)	2006-01-27	2006-03-08	Novartis Ag	Organic compounds
US20100216734A1 (en)	2006-03-08	2010-08-26	Braincells, Inc.	Modulation of neurogenesis by nootropic agents
GB0605691D0 (en) *	2006-03-21	2006-05-03	Novartis Ag	Organic Compounds
AU2007249399A1 (en)	2006-05-09	2007-11-22	Braincells, Inc.	Neurogenesis by modulating angiotensin
GB0613162D0 (en) *	2006-06-30	2006-08-09	Novartis Ag	Organic compounds
CA2658835A1 (en) *	2006-08-23	2008-02-28	Novartis Ag	Use of pkc inhibitors in ocular diseases
US20100184806A1 (en)	2006-09-19	2010-07-22	Braincells, Inc.	Modulation of neurogenesis by ppar agents
TW200838536A (en)	2006-11-29	2008-10-01	Takeda Pharmaceutical	Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
JP2010512335A (ja) *	2006-12-07	2010-04-22	ノバルティスアーゲー	移植におけるｐｋｃ阻害剤の使用
ES2410955T3 (es)	2006-12-19	2013-07-04	Novartis Ag	Derivados de indolilmaleimida como inhibidores de la quinasa
EP2154969B1 (en)	2007-05-16	2015-11-18	The Brigham and Women's Hospital, Inc.	Treatment of synucleinopathies
EP2468301A1 (en)	2007-05-29	2012-06-27	Novartis AG	New indications for anti-IL-1-beta therapy
US20090054513A1 (en) *	2007-08-22	2009-02-26	Response Scientific, Inc.	Method of managing blood glucose levels, insulin levels and/or insulin receptor functionality in individuals with diabetes, polycystic ovarian syndrome and/or alzheimer's disease
US7943163B2 (en) *	2007-08-22	2011-05-17	Response Scientific, Inc.	Medical food or nutritional supplement, method of manufacturing same, and method of managing diabetes
WO2009060035A1 (en)	2007-11-08	2009-05-14	Novartis Ag	Gene expression signatures for chronic/sclerosing allograft nephropathy
AR069799A1 (es) *	2007-12-21	2010-02-17	Novartis Ag	Composicion farmaceutica
US8268834B2 (en)	2008-03-19	2012-09-18	Novartis Ag	Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme
ES2331451B1 (es) *	2008-06-30	2010-10-21	Consejo Superior De Investigaciones Cientificas (Csic)	Inmunosupresor basado en la interrupcion de la interaccion tcr-nck.
WO2010042433A1 (en)	2008-10-06	2010-04-15	Bristol-Myers Squibb Company	Combination of cd137 antibody and ctla-4 antibody for the treatment of proliferative diseases
DE202008014557U1 (de)	2008-10-27	2009-03-12	Eberhard-Karls-Universität Tübingen Universitätsklinikum	Therapeutische Verwendung
WO2010099217A1 (en)	2009-02-25	2010-09-02	Braincells, Inc.	Modulation of neurogenesis using d-cycloserine combinations
CN101671329B (zh) *	2009-06-17	2012-11-07	东华大学	3-氨基醇取代的吲哚马来酰亚胺化合物、其制备和应用
CA2767616A1 (en)	2009-07-09	2011-01-13	The Scripps Research Institute	Gene expression profiles associated with chronic allograft nephropathy
TWI535440B (zh)	2009-10-26	2016-06-01	Ｌｇ生命科學有限公司	包括吲哚化合物之醫藥組成物
US8791100B2 (en)	2010-02-02	2014-07-29	Novartis Ag	Aryl benzylamine compounds
CN102821759A (zh)	2010-03-30	2012-12-12	诺华有限公司	用于治疗具有慢性活性b细胞受体信号传导的b细胞淋巴瘤的pkc抑制剂
UA112517C2 (uk)	2010-07-06	2016-09-26	Новартіс Аг	Тетрагідропіридопіримідинові похідні
US8785648B1 (en)	2010-08-10	2014-07-22	The Regents Of The University Of California	PKC-epsilon inhibitors
SMT201700185T1 (it)	2010-08-23	2017-05-08	Univ Texas	Anticorpi anti-ox40 e metodi di uso degli stessi
CZ305457B6 (cs)	2011-02-28	2015-09-30	Ústav organické chemie a biochemie, Akademie věd ČR v. v. i.	Pyrimidinové sloučeniny inhibující tvorbu oxidu dusnatého a prostaglandinu E2, způsob výroby a použití
UY34072A (es)	2011-05-17	2013-01-03	Novartis Ag	Derivados sustituidos de indol
JP2014518256A (ja)	2011-06-27	2014-07-28	ノバルティスアーゲー	テトラヒドロ−ピリド−ピリミジン誘導体の固体形態および塩類
KR20140058543A (ko)	2011-07-08	2014-05-14	노파르티스 아게	신규 피롤로 피리미딘 유도체
WO2013057711A1 (en)	2011-10-21	2013-04-25	Novartis Ag	Quinazoline derivatives as pi3k modulators
US20140348848A1 (en)	2011-12-02	2014-11-27	Dhananjay Kaul	Anti-il-1beta (interleukin-1beta) antibody-based prophylactic therapy to prevent complications leading to vaso-occlusion in sickle cell disease
DK2790705T3 (en)	2011-12-15	2018-03-12	Novartis Ag	Use of inhibitors of the activity or function of PI3K
JP5903499B2 (ja)	2011-12-22	2016-04-13	ノバルティスアーゲー	ジヒドロ−ベンゾ−オキサジンおよびジヒドロ−ピリド−オキサジン誘導体
WO2013093850A1 (en)	2011-12-22	2013-06-27	Novartis Ag	Quinoline derivatives
US20150284364A1 (en)	2012-11-07	2015-10-08	Nicole Bieri	Substituted indole derivatives
TW201422625A (zh)	2012-11-26	2014-06-16	Novartis Ag	二氫－吡啶并－□衍生物之固體形式
BR112015012497B1 (pt)	2012-11-29	2022-05-17	Novartis Ag	Combinações e composições farmacêuticas, seus usos, preparação combinada, e embalagem comercial
WO2014117035A1 (en)	2013-01-24	2014-07-31	Transderm, Inc.	COMPOSITIONS FOR TRANSDERMAL DELIVERY OF mTOR INHIBITORS
WO2014128612A1 (en)	2013-02-20	2014-08-28	Novartis Ag	Quinazolin-4-one derivatives
WO2014174478A1 (en)	2013-04-26	2014-10-30	Novartis Ag	Pharmaceutical combinations of a pkc inhibitor and a c-met receptor tyrosine kinase inhibitor
US9657007B2 (en)	2013-09-22	2017-05-23	Calitor Sciences, Llc	Substituted aminopyrimidine compounds and methods of use
KR101630806B1 (ko)	2013-11-14	2016-06-16	대한민국	돼지의 초위성체 마커를 이용한 개체식별 방법
US9512084B2 (en)	2013-11-29	2016-12-06	Novartis Ag	Amino pyrimidine derivatives
MX2016012574A (es)	2014-03-28	2017-09-26	Calitor Sciences Llc	Compuestos heteroarilo sustituidos y metodos de uso.
EP3134397A1 (en)	2014-04-24	2017-03-01	Novartis AG	Amino pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors
KR20160145780A (ko)	2014-04-24	2016-12-20	노파르티스 아게	포스파티딜이노시톨 3-키나제 억제제로서의 아미노 피리딘 유도체
KR20160141856A (ko)	2014-04-24	2016-12-09	노파르티스 아게	포스파티딜이노시톨 3-키나제 억제제로서의 피라진 유도체
US10443100B2 (en)	2014-05-22	2019-10-15	The Scripps Research Institute	Gene expression profiles associated with sub-clinical kidney transplant rejection
EP3146077A4 (en)	2014-05-22	2018-05-02	The Scripps Research Institute	Tissue molecular signatures of kidney transplant rejections
US11104951B2 (en)	2014-05-22	2021-08-31	The Scripps Research Institute	Molecular signatures for distinguishing liver transplant rejections or injuries
EP3180003B1 (en)	2014-07-01	2022-01-12	The Regents of the University of California	Pkc-epsilon inhibitors
JO3589B1 (ar)	2014-08-06	2020-07-05	Novartis Ag	مثبطات كيناز البروتين c وطرق استخداماتها
CA2984794A1 (en)	2015-05-07	2016-11-10	Agenus Inc.	Anti-ox40 antibodies and methods of use thereof
WO2017044434A1 (en)	2015-09-11	2017-03-16	Sunshine Lake Pharma Co., Ltd.	Substituted heteroaryl compounds and methods of use
IL299072A (en)	2015-12-02	2023-02-01	Memorial Sloan Kettering Cancer Center	Antibodies and methods for using them
MA46770A (fr)	2016-11-09	2019-09-18	Agenus Inc	Anticorps anti-ox40, anticorps anti-gitr, et leurs procédés d'utilisation
JP7108631B2 (ja)	2017-01-06	2022-07-28	パルヴェラセラピューティクス、インク．	ｍＴＯＲ阻害剤の無水組成物およびその使用方法
WO2018175302A1 (en)	2017-03-20	2018-09-27	Sienna Biopharmaceuticals, Inc.	Polymer conjugates targeting c-src with reduced exposure
WO2018175340A1 (en)	2017-03-20	2018-09-27	Sienna Biopharmaceuticals, Inc.	Reduced exposure conjugates modulating therapeutic targets
US10683297B2 (en)	2017-11-19	2020-06-16	Calitor Sciences, Llc	Substituted heteroaryl compounds and methods of use
AU2019209960B2 (en)	2018-01-20	2023-11-23	Sunshine Lake Pharma Co., Ltd.	Substituted aminopyrimidine compounds and methods of use
CN110551103B (zh) *	2018-05-30	2022-08-23	北京大学深圳研究生院	一种jak3选择性抑制剂
US11000513B2 (en)	2018-07-02	2021-05-11	Palvella Therapeutics, Inc.	Anhydrous compositions of mTOR inhibitors and methods of use
BR112021023054A2 (pt)	2019-05-23	2022-03-29	Novartis Ag	Formas cristalinas de um inibidor de btk

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CZ280738B6 (cs) *	1988-02-10	1996-04-17	F. Hoffmann - La Roche And Co., Aktiengesellschaft	Substituované pyrroly, jejich použití pro výrobu léčiv a léčiva na jejich bázi
MC2096A1 (fr) *	1989-02-23	1991-02-15	Hoffmann La Roche	Pyrroles substitues
CA2338866A1 (en) *	1998-07-30	2000-02-10	Japan Tobacco Inc.	Disubstituted maleimide compound and pharmaceutical use thereof
US6281356B1 (en)	1999-12-22	2001-08-28	Hoffmann-La Roche Inc.	Substituted pyrroles
YU4403A (sh)	2000-07-27	2006-05-25	F. Hoffmann-La Roche Ag.	Derivati 3-indolil-4-fenil-1h-pirol-2,5-diona, kao inhibitori glikogen sintaza kinaze-3 beta
US6645970B2 (en) *	2000-11-07	2003-11-11	Novartis Ag	Indolylmaleimide derivatives
AU2002221810B2 (en) *	2000-11-07	2005-06-23	Novartis Ag	Indolylmaleimide derivatives as protein kinase C inhibitors
PE20040079A1 (es) *	2002-04-03	2004-04-19	Novartis Ag	Derivados de indolilmaleimida
US20070142401A1 (en) *	2003-10-27	2007-06-21	Novartis Ag	Indolyl-pyrroledione derivatives for the treatment of neurological and vascular disorders related to beta-amyloid generation and/or aggregation

2003
- 2003-04-01 PE PE2003000330A patent/PE20040079A1/es not_active Application Discontinuation
- 2003-04-01 TW TW092107388A patent/TWI324064B/zh not_active IP Right Cessation
- 2003-04-01 AR ARP030101128A patent/AR039209A1/es active IP Right Grant
- 2003-04-01 TW TW097141220A patent/TW200918046A/zh unknown
- 2003-04-02 RU RU2004132203/04A patent/RU2340610C2/ru not_active IP Right Cessation
- 2003-04-02 US US10/510,027 patent/US20050119274A1/en not_active Abandoned
- 2003-04-02 KR KR1020077007917A patent/KR100942329B1/ko not_active Expired - Fee Related
- 2003-04-02 CN CNB038053438A patent/CN100351251C/zh not_active Expired - Lifetime
- 2003-04-02 PT PT03720413T patent/PT1490355E/pt unknown
- 2003-04-02 WO PCT/EP2003/003470 patent/WO2003082859A1/en not_active Ceased
- 2003-04-02 BR BR0308979-7A patent/BR0308979A/pt not_active IP Right Cessation
- 2003-04-02 EP EP03720413A patent/EP1490355B1/en not_active Expired - Lifetime
- 2003-04-02 DK DK03720413.8T patent/DK1490355T3/da active
- 2003-04-02 CA CA2477774A patent/CA2477774C/en not_active Expired - Lifetime
- 2003-04-02 IL IL16389203A patent/IL163892A0/xx unknown
- 2003-04-02 MX MXPA04009632A patent/MXPA04009632A/es active IP Right Grant
- 2003-04-02 MY MYPI20031225A patent/MY137566A/en unknown
- 2003-04-02 JP JP2003580325A patent/JP4247125B2/ja not_active Expired - Lifetime
- 2003-04-02 SI SI200332053T patent/SI1490355T1/sl unknown
- 2003-04-02 NZ NZ535613A patent/NZ535613A/en not_active IP Right Cessation
- 2003-04-02 KR KR1020047015591A patent/KR100886521B1/ko not_active Expired - Fee Related
- 2003-04-02 AT AT03720413T patent/ATE517888T1/de active
- 2003-04-02 AU AU2003224031A patent/AU2003224031B2/en not_active Expired
- 2003-04-02 PL PL371322A patent/PL213480B1/pl unknown
2004
- 2004-08-27 EC EC2004005254A patent/ECSP045254A/es unknown
- 2004-09-15 CO CO04091784A patent/CO5611127A2/es active IP Right Grant
- 2004-10-26 NO NO20044613A patent/NO329166B1/no not_active IP Right Cessation
2006
- 2006-10-12 US US11/546,693 patent/US7235555B2/en not_active Expired - Lifetime
- 2006-10-12 US US11/546,690 patent/US7358253B2/en not_active Expired - Lifetime
2007
- 2007-10-25 US US11/977,565 patent/US20080108628A1/en not_active Abandoned
2008
- 2008-02-21 US US12/034,675 patent/US7534808B2/en not_active Expired - Lifetime
- 2008-12-12 EC EC2008005254A patent/ECSP085254A/es unknown
2011
- 2011-10-27 CY CY20111101021T patent/CY1111982T1/el unknown

Also Published As

Publication number	Publication date
CN100351251C (zh)	2007-11-28
RU2004132203A (ru)	2005-07-10
EP1490355B1 (en)	2011-07-27
MXPA04009632A (es)	2005-01-11
PT1490355E (pt)	2011-11-03
ATE517888T1 (de)	2011-08-15
AU2003224031A1 (en)	2003-10-13
AU2003224031B2 (en)	2007-06-28
JP4247125B2 (ja)	2009-04-02
PL371322A1 (pl)	2005-06-13
AR039209A1 (es)	2005-02-09
KR100942329B1 (ko)	2010-02-12
US20050119274A1 (en)	2005-06-02
CN1639153A (zh)	2005-07-13
US20070032507A1 (en)	2007-02-08
JP2005527563A (ja)	2005-09-15
CA2477774A1 (en)	2003-10-09
KR20070043900A (ko)	2007-04-25
TW200306818A (en)	2003-12-01
DK1490355T3 (da)	2011-11-21
CY1111982T1 (el)	2015-11-04
BR0308979A (pt)	2005-01-04
PL213480B1 (pl)	2013-03-29
US20080108628A1 (en)	2008-05-08
ECSP085254A (es)	2009-01-30
IL163892A0 (en)	2005-12-18
CO5611127A2 (es)	2006-02-28
WO2003082859A1 (en)	2003-10-09
TW200918046A (en)	2009-05-01
US7534808B2 (en)	2009-05-19
NZ535613A (en)	2007-07-27
US20070037826A1 (en)	2007-02-15
EP1490355A1 (en)	2004-12-29
US7358253B2 (en)	2008-04-15
US20080146578A1 (en)	2008-06-19
ECSP045254A (es)	2004-09-28
NO20044613L (no)	2004-10-26
KR20040094901A (ko)	2004-11-10
TWI324064B (en)	2010-05-01
SI1490355T1 (sl)	2011-11-30
CA2477774C (en)	2011-03-15
PE20040079A1 (es)	2004-04-19
US7235555B2 (en)	2007-06-26
RU2340610C2 (ru)	2008-12-10
KR100886521B1 (ko)	2009-03-02
MY137566A (en)	2009-02-27

Legal Events

Date	Code	Title	Description
2014-11-24	MM1K	Lapsed by not paying the annual fees

Publication	Publication Date	Title
NO329166B1 (no)	2010-09-06	Indolylmaleimidderivater, fremgangsmate for fremstilling derav, anvendelse av forbindelsene samt farmasoytisk sammensetning inneholdende en slik forbindelse.
EP1597250B1 (en)	2010-04-07	Indolylmaleimide derivatives
EP1745037B1 (en)	2013-01-02	Indolylmaleimide derivatives as inhibitors for the treatment of graft rejection or autoimmune diseases
ZA200406545B (en)	2006-05-31	Indolymaleimide derivatives